title: HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma.
abstract: Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease influenced by genetic and environmental factors. The role of the HLA system in tumor antigen presentation could be involved in susceptibility and disease control. We analyzed the phenotypic frequencies of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 in 250 DLBCLs, comparing them with 1940 healthy individuals. We also evaluated the influence of HLA polymorphisms on survival in those patients treated with curative intention using cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimen without (n = 64, 26%) or with (n = 153, 61%) rituximab. DLBCL patients have a higher phenotypic frequency of HLA-DRB1*01 (29% vs 19.5%, P = .0008, Pc = .0104) and a lower frequency of HLA-C*03 (6.4% vs 17.9%, P < .0005, Pc = .007) compared with healthy individuals. Irrespective of the age-adjusted International Prognostic Index, those patients receiving a CHOP-like plus rituximab regimen and carrying the HLA-B44 supertype had worse 5-year progression-free (54% vs 71%, P = .019) and 5-year overall (71% vs 92%, P = .001) survival compared with patients without this supertype. Our data suggest that some HLA polymorphisms influence the development and outcome of DLBCL, allowing the identification of an extremely good-risk prognostic subgroup. However, these results are preliminary and need to be validated in order to exclude a possible population effect.
authors.affiliation: Department of Hematology, University Hospital of Salamanca, Paseo de San Vicente 58-182, Salamanca, Spain.
authors.forename: Miguel
authors.initials: M
authors.lastname: Alcoceba
authors.forename: Elena
authors.initials: E
authors.lastname: Sebastián
authors.forename: Luis
authors.initials: L
authors.lastname: Marín
authors.forename: Ana
authors.initials: A
authors.lastname: Balanzategui
authors.forename: M Eugenia
authors.initials: ME
authors.lastname: Sarasquete
authors.forename: M Carmen
authors.initials: MC
authors.lastname: Chillón
authors.forename: Cristina
authors.initials: C
authors.lastname: Jiménez
authors.forename: Noemí
authors.initials: N
authors.lastname: Puig
authors.forename: Rocío
authors.initials: R
authors.lastname: Corral
authors.forename: Emilia
authors.initials: E
authors.lastname: Pardal
authors.forename: Carlos
authors.initials: C
authors.lastname: Grande
authors.forename: José Luis
authors.initials: JL
authors.lastname: Bello
authors.forename: Carmen
authors.initials: C
authors.lastname: Albo
authors.forename: Fátima
authors.initials: F
authors.lastname: de la Cruz
authors.forename: Carlos
authors.initials: C
authors.lastname: Panizo
authors.forename: Alejandro
authors.initials: A
authors.lastname: Martín
authors.forename: Eva
authors.initials: E
authors.lastname: González-Barca
authors.forename: M Dolores
authors.initials: MD
authors.lastname: Caballero
authors.forename: Jesús F
authors.initials: JF
authors.lastname: San Miguel
authors.forename: Ramón
authors.initials: R
authors.lastname: García-Sanz
authors.forename: Marcos
authors.initials: M
authors.lastname: González
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D016022:Case-Control Studies; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005787:Gene Frequency; D006680:HLA Antigens / Q000235:genetics*; D059811:HLA-DRB1 Chains / Q000235:genetics; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011110:Polymorphism, Genetic; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors; D000069283:Rituximab; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D006680:HLA Antigens; D059811:HLA-DRB1 Chains; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone